-
Sign In
- Sony Biotechnology
- Sony Biotechnology
CD106 is a 110 kD glycosylphosphatidylinositol (GPI)-linked transmembrane protein, also known as VCAM-1 and INCAM-110. It is constitutively expressed on bone marrow stromal cells, myeloid progenitors, splenic dendritic cells, activated endothelial cells, as well as some lymphocytes. CD106 expression can be upregulated on endothelial cells by inflammatory cytokines. CD106 is involved in adhesion and acts as a counter-receptor for VLA-4 (α4/β1 integrin) and LPAM-1 (α4/β7 integrin). The 429 antibody has been reported to partially block VCAM-1-mediated binding.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 microg per 106 cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.
1. Kinashi T, et al. 1995. J. Leukoc. Biol. 57:168. (IP)
2. Koni PA, et al. 2001. J. Exp. Med. 193:741. (IHC)
3. Ishiyama N, et al. 1998. Pathobiology 66:274. (IHC)
4. Kinashi T, et al. 1994. Blood Cells 20:25. (Block)
5. Baron JL, et al. 1994. J. Clin. Invest. 93:1700. (Block IHC)
6. Buck CA, et al. 1996. Cell Adhes. Commun. 4:69. (IHC)
7. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
8. Meunier MC, et al. 2005. Nature Medicine 11:1222. (Block) PubMed
9. Wang C, et al. 2014. J Exp Med. PubMed